Nanocarrier for poorly water-soluble anticancer drugs—barriers of translation and solutions
M Narvekar, HY Xue, JY Eoh, HL Wong - Aaps Pharmscitech, 2014 - Springer
Many existing chemotherapeutic drugs, repurposed drugs and newly developed small-
molecule anticancer compounds have high lipophilicity and low water-solubility. Currently …
molecule anticancer compounds have high lipophilicity and low water-solubility. Currently …
Poly (ethylene glycol)–polylactide micelles for cancer therapy
J Wang, S Li, Y Han, J Guan, S Chung… - Frontiers in …, 2018 - frontiersin.org
For the treatment of malignancy, many therapeutic agents, including small molecules,
photosensitizers, immunomodulators, proteins and genes, and so forth, have been loaded …
photosensitizers, immunomodulators, proteins and genes, and so forth, have been loaded …
Nanocarriers for anticancer drugs-new trends in nanomedicine
J Drbohlavova, J Chomoucka, V Adam… - Current drug …, 2013 - ingentaconnect.com
This review provides a brief overview of the variety of carriers employed for targeted drug
delivery used in cancer therapy and summarizes advantages and disadvantages of each …
delivery used in cancer therapy and summarizes advantages and disadvantages of each …
How nanotechnology can enhance docetaxel therapy
Docetaxel has been recognized as one of the most efficient anticancer drugs over the past
decade; however, its poor water solubility and systemic toxicity have greatly limited its …
decade; however, its poor water solubility and systemic toxicity have greatly limited its …
Drug delivery system targeting advanced hepatocellular carcinoma: Current and future
Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat
due to long latent period before detection, multidrug resistance and severe drug-related …
due to long latent period before detection, multidrug resistance and severe drug-related …
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC
There is an urgent need for new therapeutics for the treatment of aggressive and metastatic
refractory human non-small–cell lung cancer (NSCLC). Antiangiogenesis therapy and …
refractory human non-small–cell lung cancer (NSCLC). Antiangiogenesis therapy and …
Peptide-directed hierarchical mineralized silver nanocages for anti-tumor photothermal therapy
The size and morphology of metals determine their plasmon resonances. How to elegantly
tune their architectures to obtain optical properties as required (eg, strong absorption in the …
tune their architectures to obtain optical properties as required (eg, strong absorption in the …
The development of site-specific drug delivery nanocarriers based on receptor mediation
Since they were first reported in 1980, site-specific drug delivery nanocarriers have
progressed greatly with the development of nanotechnology and biotechnology, especially …
progressed greatly with the development of nanotechnology and biotechnology, especially …
Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy
The treatment of aggressive non-small-cell lung cancer (NSCLC) depends on the creation of
new therapeutic regimens in clinical settings. In this study, we developed a Lipid/Calcium …
new therapeutic regimens in clinical settings. In this study, we developed a Lipid/Calcium …
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy
Nucleoside analogs are a significant class of anti-cancer agent. As prodrugs, they terminate
the DNA synthesis upon transforming to their active triphosphate metabolites. We have …
the DNA synthesis upon transforming to their active triphosphate metabolites. We have …